n Abstract: Central sensitization (CS) has been proposed as a common pathophysiological mechanism to explain related syndromes for which no specific organic cause can be found. The term ''central sensitivity syndrome (CSS)'' has been proposed to describe these poorly understood disorders related to CS. The goal of this investigation was to develop the Central Sensitization Inventory (CSI), which identifies key symptoms associated with CSSs and quantifies the degree of these symptoms. The utility of the CSI, to differentiate among different types of chronic pain patients who presumably have different levels of CS impairment, was then evaluated. Study 1 demonstrated strong psychometric properties (test-retest reliability = 0.817; Cronbach's alpha = 0.879) of the CSI in a cohort of normative subjects. A factor analysis (including both normative and chronic pain subjects) yielded 4 major factors (all related to somatic and emotional symptoms), accounting for 53.4% of the variance in the dataset. In Study 2, the CSI was administered to 4 groups: fibromyalgia (FM); chronic widespread pain without FM; work-related regional chronic low back pain (CLBP); and normative control group. Analyses revealed that the patients with FM reported the highest CSI scores and the normative population the lowest (P < 0.05). Analyses also demonstrated that the prevalence of previously diagnosed CSSs and related disorders was highest in the FM group and lowest in the normative group (P < 0.001). Taken together, these 2 studies demonstrate the psychometric strength, clinical utility, and the initial construct validity of the CSI in evaluating CS-related clinical symptoms in chronic pain populations. j
INTRODUCTION
Physical symptoms that are unexplained by organic cause are a relatively common phenomenon. It is estimated that modern diagnostic testing can find no organic explanation for 10% of reported and persisting physical symptoms. 1 Furthermore, the occurrence of multiple somatic symptoms is associated with higher rates of psychopathology and predicts poorer treatment outcomes and higher healthcare utilization. [2] [3] [4] [5] Such nonorganic symptom complaints have traditionally been grouped into separate syndromes, such as fibromyalgia (FM), chronic fatigue, irritable bowel (IBS), and temporomandibular joint (TMJ) disorders. Historically, different terms have been used to group these types of somatization disorders, including ''functional syndromes, '' 6,7 ''medically unexplained symptoms,'' 8, 9 and ''bodily distress syndrome.'' 10 These syndromes share many common features, including pain, fatigue, poor sleep, cognitive deficits, headaches, anxiety, and depression, suggesting that they may share a common etiology. 9 Recent evidence has found that central sensitization (CS), which involves an abnormal and intense enhancement of pain by mechanisms in the central nervous system, may be the common link between these disorders. 11 Yunus 12 has
proposed the term ''central sensitivity syndrome'' (CSS) for nonorganic disorders that are presumed to share this CS etiology. Unlike previous terminology for these nonorganic disorders, which propose no common pathophysiological mechanism, the CSS model provides a very appealing theoretical construct for categorizing these related syndromes. Within this model, symptom presentations that have previously been viewed as individual somatoform disorders can now be viewed as many forms of a common CSS, with CS as a root cause. [13] [14] [15] .
Central sensitization is characterized by allodynia (painful sensation to a normally nonpainful stimulus, such as touch), hyperalgesia (excessive sensitivity to a normally painful stimulus, such as pressure), expansion of the receptive field (pain that extends beyond the area of peripheral nerve supply), and unusually prolonged pain after the stimulus has been removed (usually burning, throbbing, tingling, or numbness). A number of explanations have been proposed to explain the development of CS, including dysregulation in both ascending and descending central nervous system pathways as a result of physical trauma and sustained pain impulses, and the chronic release of pro-inflammatory cytokines by the immune system, as a result of physical trauma or viral infection. 16 Other non-CS biological mechanisms have also been associated with CSS disorders, such as a dysfunction of the stress system, including the hypothalamic-pituitaryadrenal axis. 17 In addition, it is well recognized that psychiatric disorders, including anxiety, panic, and depression, are often associated with CSSs. [18] [19] [20] [21] Because of the interaction between psychosocial factors and biological mechanisms, it has been recommended that CSSs be viewed within a biopsychosocial model. 22 Evidence for CS in many CSSs, including FM, TMJ, and IBS, has been demonstrated by reduced subjective pain thresholds in patients vs. pain-free controls to various stimuli, such as electrical, pressure, cold, and heat. Objective measures of CS (not relying on subjective self-report) have been demonstrated with brain imaging and with nocioceptive spinal reflex tests. 22, 23 However, evidence of CS has not been found in all disorders in the proposed CSS family. 11 The reduced pain threshold phenomenon, which corresponds to CS, has also been found in patients outside of the CSS family including regional low back pain. It has been suggested that changes in central pain processing in some individuals with regional pain can result in the later development of chronic widespread pain (CWP). 24 In fact, longitudinal studies have found that about one quarter of patients with chronic neck or back pain will develop CWP. 25 A variety of self-report measures have been developed to evaluate individual symptom manifestations of CSS, including FM; [26] [27] [28] [29] [30] [31] [32] [33] [34] chronic fatigue syndrome; 35, 36 and IBS. 37, 38 Other instruments are available for measuring comorbid medical conditions, but none of which are focused on CSS. [39] [40] [41] A single self-report instrument that identifies key comorbid symptoms associated with CS and CSSs, and which quantifies the degree of these symptoms, has not previously appeared in the literature and is therefore likely to be a useful clinical screening tool.
The purpose of this study was to develop such a new self-report measure designed to assess key somatic and emotional complaints often associated with CSS. The item pool was created from a literature search of comorbid symptoms and conditions of FM and other CSSs (see Table 1 ). The clinical goal of this screening instrument, the Central Sensitization Inventory or CSI, is to help better assess symptoms thought to be associated with CS in order to aid physicians and other clinicians in syndrome categorization, sensitivity, severity identification, and treatment planning, to help minimize, or possibly avoid, unnecessary diagnostics and treatment procedures. For this purpose, the psychometric validity and clinical utility of the CSI were evaluated in 2 separate studies. First, the CSI was evaluated assessing test-retest reliability and internal consistency. Also, a factor analysis was utilized to identify specific items that load onto distinguishable factors. In the second study, validation was established by comparing scores between 4 subject groups, including FM, CWP, regional chronic low back pain (CLBP), and a normative control group. It was hypothesized that the degree of CSS symptomatology, and resulting scores on the CSI, would be highest in the FM group and progressively less in the other 3 groups.
METHODS

Study 1
This initial component of the present investigation developed the CSI and evaluated its psychometric properties. Somatic and emotional symptoms that have been found to be associated with CS and CSSs, based in part upon a literature search of comorbid symptoms and disorders associated with FM and other CSSs, were used in the development of the CSI items (Table 1) .
Instrument development. An interdisciplinary team that included physicians (psychiatrists and orthopedic surgeons), rehabilitation specialists, clinical psychologists, health psychologists, and psychophysiological specialists, who work exclusively with individuals with chronic pain conditions, developed the items for this Inventory. The resultant CSI contains a Part A of 25 statements related to current health symptoms. Each of these items is measured on a 5-point temporal Likert scale, with the following numeric rating scale: never (0), rarely (1), sometimes (2), often (3), and always (4) . A cumulative score ranges from 0 to 100. Additionally, information is collected in Part B on previously diagnosed CSS and related conditions. The CSI is presented in Appendix A and B.
Reliability study. The participants in the reliability study were characterized as ''normal'' in that they were from a general population not know to currently be in treatment for chronic pain. These participants included undergraduate students, graduate students, staff, and faculty members at The University of Texas at Arlington. The Institutional Review Board at The University of Texas at Arlington approved this reliability study, and all participants provided written informed consent prior to participation. The demographic make-up of the participants in the reliability portion of the study was 29.4% male; 21.2% Asian, 18.4% Black people, 17.0% Hispanic, 36.4% White people, and 7.0% Other/Multiracial. The mean age of this sample was 22.4 years (SD = 4.7 years). A total of 149 participants who completed the first and second administrations of the assessment were used in this portion of the study. The CSI was administered at 2 time points, approximately 5 days apart.
Factor analysis. Completed questionnaires for 359 participants were considered for the factor analysis. These participants included both individuals from a general population and patients with chronic pain conditions. In addition to the normative group, the questionnaires from 210 consecutive patients with chronic disabling occupational musculoskeletal disorders (CDOMD), attending a functional restoration rehabilitation program at the Productive Rehabilitation Institute of Dallas for Ergonomics, Dallas, TX (PRIDE), a regional referral center for chronic pain patients, were used. The CSI was administered to the patients with CDOMD upon admission, prior to treatment.
Statistical analyses.
For the test-retest portion of Study 1, correlational comparisons were made for each of the 25 items, along with the overall sum score. Internal consistency for the first assessment was also evaluated. The data were analyzed using SPSS v.18. For the test-retest analysis, a Pearson's correlation (r) was used to determine the item correlation between each administration of the assessment. Cronbach's alpha was used to determine the internal consistency of the responses. The significance level for all analyses was set at alpha = 0.05. For the factor analysis, a principal component analysis was conducted, using a Promax Rotation. Whiplash/cervical injury 47, [61] [62] [63] Cognitive impairments 64, 65 Multiple chemical sensitivities 66 Chronic hives 67 Psychological disturbance, including anxiety, panic, and depression [68] [69] [70] [71] Post-traumatic stress disorder (PTSD) 72 Childhood abuse/trauma [73] [74] [75] Factors were considered for eigenvalues greater than one. The cutoff for the loadings was set at 0.4.
Study 2
The purpose of this study was to evaluate the utility of the CSI to differentiate among different subject groups of chronic pain patients, presumed to have different degrees of CSS-related symptomatology, and a normative control group.
Participants. A total of 105 chronic pain patients and 40 healthy college students were recruited from PRIDE and The University of Texas at Arlington, respectively. The criteria for participation in the PRIDE treatment program were as follows: (1) a minimum of 3 months elapsed between the date of injury and treatment; (2) primary and/or secondary care were unsuccessful or unnecessary; (3) surgery either was not an option or did not produce relief from the injury; (4) severe pain and functional limitations remained; and (5) patients must communicate in English or Spanish.
There were 4 subsamples of subjects in this study: Arlington, who were recruited from the university-wide subject pool. No subjects in this group were known to be engaged in any current medical intervention for chronic pain.
Design and statistical analyses. The CSI, which was developed in Study 1, was used in this validation study. This study was designed to evaluate the mean score differences in the CSI among the 4 subgroups. Chi-square and univariate analyses of variance (ANOVAs) were employed for demographic analyses. Statistical analyses of group mean differences were conducted using analysis of covariance (ANCOVA). A P value of 0.05 was set as the critical value. Post hoc analyses, using the Bonferroni criterion, were conducted to investigate which groups were considered statistically different. The effect size x 2 was also calculated for the group differences found by these analyses.
RESULTS
Study 1
An item analysis was conducted using a test-retest reliability assessment. The test-retest correlation for the total score was 0.817, indicating a high level of reliability between administrations. The means, standard deviations, and test-retest correlations for each item are shown in Table 2 . All item-analysis correlations were found to be statistically significant. To determine the internal consistency of the items on the measure, Cronbach's alpha was calculated to be 0.879. This indicates that the items within the scale are indeed measuring a similar construct. Table 3 shows the loadings for the pattern matrix for the factor analysis, including the specific CSI question items that contributed to the factors. The factor analysis yielded 4 factors that accounted for 53.4% of the variance in the dataset. The factors were labeled for meaningfulness, and the variance is provided below:
Factor 1 -Physical Symptoms (30.9%) Factor 2 -Emotional Distress (7.2%) Factor 3 -Headache/Jaw Symptoms (10.1%) Factor 4 -Urological Symptoms (5.2%)
Study 2
The basic demographic variables and total CSI scores for the 4 subsamples are presented in Table 4 . There were statistically significant differences among the 4 groups regarding age and gender, F (3,141) = 76.42, P < 0.001; v 2 (3) = 36.89, P < 0.001, respectively. In order to obtain the purer effect of group differences on
Validation of the Central Sensitization Inventory • 279 the CSI scores, gender and age were controlled for by using an ANCOVA. There was a significant effect of clinical groups, after controlling for the effect of age and gender, F (3,139) = 9.22, P < 0.05, with an effect size, x 2 = 0.01. The Bonferroni post hoc test indicated that patients with FM reported the highest CSI scores ( x = 58.2, range = 34 to 78) and the normative control subjects reported the lowest CSI scores ( x = 28.4, range = 4 to 55). There was no statistical difference between the CWP-only and CLBP groups. Analyses were also conducted to evaluate the prevalence of the 10 disorders in Part B of the CSI among the 4 comparison groups. As can be seen in Table 4 , there were significantly different rates of these disorders across the groups, F (3,114) = 13.96, P < 0.001, with an effect size, x 2 = 0.15. Again, the FM group ( x = 3.4 diagnoses) was significantly different from the other 2 chronic pain groups and the normative group ( x = 0.5 diagnoses).
DISCUSSION
A growing body of evidence is demonstrating that central sensitization represents a common pathophysiological mechanism for the overlapping clinical features of CSS such as FM, chronic fatigue, IBS, and TMJ. 16 Within this emerging model, one can view the symptoms of CSS not as individual disorders, but as different manifestations of a common etiology. The purpose of the present investigation was to develop a comprehensive inventory that broadly assesses overlapping dimensions of CSS and quantifies the degree of CSS symptomatology. This measure was developed by a multi-and interdisciplinary team that specializes in assessing and treating patients with chronic pain conditions.
As shown in Appendix A and B, the CSI consists of 2 sections, Parts A and B. Part A contains 25 items with a range for the total score from 0 to 100. The item pool is intended to provide an overview of presenting symptoms that are common to CSS, with higher scores associated with a higher degree of symptomatology. Part B identifies whether one has been diagnosed by a physician with specific disorders within the CSS family, as well as related disorders, including anxiety and depression. Because co-occurrence of these disorders in patients diagnosed with CSS has been relatively well established, 43 clinicians should consider the presence of a CSS in patients who endorse one or more disorders in this section (particularly when accompanied by a high CSI score from Part A). In Study 1, focusing on Part A of the instrument, a ''normal'' population demonstrated a high degree of test-retest reliability, as well as a high Cronbach's alpha. Thus, the reliability of this assessment is psychometrically sound. This study also demonstrated that 4 factors accounted for 53.4% of the variance in the dataset (Physical Symptoms, Emotional Distress, Headache/Jaw, and Urological Symptoms Factors). Each of these factors related in some way to symptoms common in the highly heterogeneous domain of CSS.
In Study 2, comparisons of the 4 subpopulations were made. FM was presumed to have the highest level of CSS symptomatology, and CWP without FM, CLBP, and normative control subjects were presumed to have progressively less. In evaluating Part A of the CSI, the FM group was statistically distinguishable from the CWP and CLBP groups and all 3 chronic pain groups were statistically distinguishable from the normative control group. The high CSS (FM) group scored the highest on the total CSI scores, nearly double that of the normative group. It is also noteworthy in Study 2 that normative subjects have occasional symptoms, with the mean scores indicating that the symptoms of the 25-item CSI occur ''sometimes'' in most individuals (as can be seen in Figure 1 ). In evaluating Part B of the CSI, the FM group averaged 3.4 diagnoses, double that of the two other pain groups, while normative subjects averaged 0.5 diagnosis. It is the intent that this CSI will be a useful tool, in both general and specialty medical settings, to help identify patients whose presenting medical issues may be comorbid symptoms of CSS. This identification can then help guide the practitioner's treatment approach. Patients with regional and specific symptoms, which appear unrelated to CS and other comorbid indications of CSS, can be guided through appropriate diagnostic testing and symptom-specific treatments and medications. For patients who report a wide range of comorbid symptoms within the CSS family, the clinician may choose to pursue fewer expensive diagnostic tests and, instead, gear treatment toward biopsychosocial symptom management strategies and toward more appropriate and effective medications. For example, dual reuptake inhibitors have been shown to target descending central pathways by enhancing serotonin and norepinephrine levels, resulting in decreased CS-related pain. 44 For those patients who present with regional pain, especially in the back or neck, a high CSI score may be predictive of future development of CSS. Longitudinal studies have found that about one quarter of patients with chronic neck or back pain will develop CWP. 25 The results of the CSI may also lead clinicians to consider other co-existing diseases with identifiable physical findings besides the presenting problem.
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A treatable associated condition should not be overlooked. Finally, it is the intent that the CSI will be a useful tool for assessing pre-to postintervention responsiveness to biopsychosocial treatments for these syndromes.
In conclusion, this article demonstrates the psychometric strength, the clinical utility, and the initial construct validity of the CSI in evaluating CS-related symptoms. The CSI is meant to give clinicians a ''heads up'' for considering the possibility of central sensitization serving as a starting point for more pragmatic therapeutic solutions. 17 By overlooking the possibility of a CSS diagnosis, time, effort, and resources may be wasted on inappropriate diagnostic testing and treatment, or in the application of invasive procedures with poor results when less expensive, and more effective, alternative interventions may be available. A limitation of the present study was the limited number of CSS comparison groups that were evaluated. Further research will be required to compare CSI scores of additional populations within the CSS family (such as chronic fatigue, headache, TMJ, and IBS), in order to identify the associations between the individual factors on the CSI and clinical CSS symptom manifestations, and to establish clinically meaningful cutoff points. 
